Jeisys

Market position

Jeisys presents itself as a leading global manufacturer of energy-based medical aesthetic devices and a K-beauty medical technology company, citing roughly 25 years of R&D and more than 15,000 installed systems worldwide, and describing Potenza as the number one RF microneedling treatment. Prior to its 2024 delisting bid it was a Kosdaq-listed company with a market capitalization of 977.9 billion won ($710.8 million) as of June 10, 2024. It is backed by ARCHIMED, described as an $8 billion healthcare investment firm.

Jeisys emphasizes dual-mode sequential monopolar-bipolar RF as delivering collagen stimulation across more skin layers than single-mode RF, needle-free and numbing-free treatment with minimal downtime versus RF microneedling, and greater comfort than HIFU through real-time temperature monitoring and cooling. It also cites real-time impedance monitoring for consistent results across skin types and tones, a broad multi-modality portfolio, peer-reviewed clinical support, and provider-first training and support rather than product sales alone.

Technology

Core technologies are radiofrequency (monopolar and bipolar, up to 400W, 14 invasive and non-invasive tips), high-intensity focused ultrasound with dual Linear and Dot modes and adjustable depth from a single cartridge, microneedle-based drug delivery, IPL with nine wavelength filters, Nd:YAG laser targeting interstitial chromophores, and CO2 laser for incision and ablation. The Density platform delivers sequential monopolar and bipolar RF in the same pulse to reach deep and superficial layers, with five levels of adjustable cooling, real-time impedance monitoring for automatic energy adjustment, energy adjustable from 0 to 8 in 0.5 increments, auto and manual modes, tip shot-life countdown, and per-pulse and cumulative energy tracking.

Go-to-market

Sales are provider-first and direct-to-practice in key markets, combined with distribution elsewhere in Asia. The company markets through medical aesthetic congresses and exhibitions (IMCAS Asia, KACAS, RADLA), its own 'Jeisys TEA' global brand symposium series, and clinician-led events such as the EYE-CONIC SUMMIT, alongside device demo requests, hands-on clinical training, real-time troubleshooting and practice-growth marketing tools for providers.

Physicians, dermatologists and aesthetic practices, including dermatology and general surgical settings, that purchase energy-based devices for patients seeking skin tightening, lifting, pigmentation, acne and scar, and body treatments.

Geography

Headquartered in South Korea, with Seoul cited as its founding location and the base for Korean market activity. It has direct operations in Japan, Australia and Vietnam plus wider Asian distribution, a North American entity, Jeisys Medical North America, at 70 Blanchard Rd, Suite 303, Burlington, MA, and a Brazilian subsidiary. It has also entered the Latin American market, with symposium and conference activity in Buenos Aires, and runs a Japanese-language site (jeisys-inc.com) alongside jeisys.com.

History

Public sources give differing founding details: ARCHIMED states Jeisys was founded in Seoul in 2001, while Korean press coverage describes the aesthetic laser maker as established in 2004. Its U.S. arm describes the phases of the business as early success in the Korean market with an IPL device (2000-2005), product line expansion into IPL, RF, CO2 laser, Q-switched Nd:YAG and RF microneedling devices (2006-2015), Asia-Pacific growth with direct operations in Japan, Australia and Vietnam (2016-2024), and accelerated expansion into the U.S. and Brazil with backing from ARCHIMED (2024-2025). The company was listed on Korea's Kosdaq market before ARCHIMED's 2024 tender offer and delisting plan.

Risks & controversies

Sources report inconsistent founding dates (2001 per ARCHIMED, 2004 per Korean press coverage). The ARCHIMED tender offer was conditional: the firm stated it would cancel the acquisition if shares tendered amounted to less than a 28.3% stake, and the plan relied on reaching at least 95% ownership to delist without minority shareholder consent under Korea's Commercial Act.